# Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder

> **NCT00481325** · PHASE2,PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 260 (actual)

## Conditions studied

- Generalized Anxiety Disorder

## Interventions

- **DRUG:** pexacerfont
- **DRUG:** escitalopram
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00481325
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2015-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00481325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00481325, "Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00481325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*